Every material Form 8-K Telomir Pharmaceuticals, Inc. has filed with the SEC since September 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Telomir Pharmaceuticals sold 4,843,300 shares of common stock at $1.16 per share in a private placement that closed on October 5, 2026, for approximately $5.6 million in gross proceeds before expenses. The company said it will use the proceeds mainly to support clinical development of Telomir-Zn, including its Phase 1/2 trial in advanced or metastatic triple-negative breast cancer, and for working capital. The new shares add to the existing share count and carry a placement agent fee and warrants, and the company must register the resale of the shares with the SEC.
4,843,300 shares sold at $1.16 per share, a 5% discount to the 10-day VWAP on Nasdaq; closing on October 5, 2026
Approximately $5.6 million gross proceeds; existing shareholder John Paul DeJoria invested an additional $1.0 million
Placement agent Alexander Capital receives a cash fee of about $455,000 (9.0% of gross proceeds) and warrants for 387,464 shares at $1.16, expiring five years after issuance
Company must file a resale registration statement with the SEC within 30 days of the closing
Telomir Pharmaceuticals announced on September 17, 2026 the publication of a peer-reviewed preclinical study in International Journal of Molecular Sciences showing Telomir-Zn improved visual function and retinal structure in a model of age-related macular degeneration. The filing contains no financial results, and the study is preclinical, so it does not change the company's oncology clinical development focus.
Study published in International Journal of Molecular Sciences, 2026, 27(18), 8265, with Telomir-Zn dosed orally for 14 days in the model
Study reported significant improvement in visual performance and restoration of thickness across multiple retinal layers
Clinical development remains focused on a Phase 1/2 trial in advanced or metastatic triple-negative breast cancer under an FDA-cleared IND
Telomir Pharmaceuticals announced preclinical research from The Ohio State University showing Telomir-Zn inhibited cell growth in human and canine osteosarcoma cell lines at similar low drug concentrations. The company said it is assessing a possible canine in vivo study while its triple-negative breast cancer program advances toward site initiation and Phase 1/2 enrollment. The filing reports no financial results, and the findings are preclinical.
Study tested Telomir-Zn on three cell lines: HOS (human), D17 (canine), and Abrams (canine).
All three osteosarcoma cell lines showed growth inhibition at similar low drug concentrations.
The company is in discussions with Ohio State and is assessing next steps for a potential canine in vivo efficacy study.
The TNBC program remains the immediate clinical focus, with an active IND cleared by the FDA.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Telomir Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →